v3.25.4
Revenue
9 Months Ended
Sep. 30, 2025
Revenue  
Revenue

18. Revenue

 

The following is a disaggregation of revenue categorized by commodities sold for the three-month and nine-month periods ended September 30, 2025 and 2024:

 

 

Three-month

 

 

Three-month

 

 

Nine-month

 

 

Nine-month

 

 

 

period ended

 

 

period ended

 

 

period ended

 

 

period ended

 

 

 

September 30,

 

 

September 30,

 

 

September 30,

 

 

September 30,

 

 

 

2025

 

 

2024 Revised (1)

 

 

2025

 

 

2024 Revised (1)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Silver

 

 

 

 

 

 

 

 

 

 

 

 

Sales revenue

 

$17,212

 

 

$13,630

 

 

$45,950

 

 

$49,011

 

Derivative pricing adjustments

 

 

(351 )

 

 

(1,547 )

 

 

755

 

 

 

(887 )

 

 

 

16,861

 

 

 

12,083

 

 

 

46,705

 

 

 

48,124

 

Zinc

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales revenue

 

$108

 

 

$9,509

 

 

$11,883

 

 

$29,431

 

Derivative pricing adjustments

 

 

73

 

 

 

235

 

 

 

155

 

 

 

890

 

 

 

 

181

 

 

 

9,744

 

 

 

12,038

 

 

 

30,321

 

Lead

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales revenue

 

$2,048

 

 

$4,482

 

 

$7,312

 

 

$14,274

 

Derivative pricing adjustments

 

 

(41 )

 

 

(105 )

 

 

(175 )

 

 

53

 

 

 

 

2,007

 

 

 

4,377

 

 

 

7,137

 

 

 

14,327

 

Other by-products

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales revenue

 

$4

 

 

$216

 

 

$354

 

 

$808

 

Derivative pricing adjustments

 

 

26

 

 

 

92

 

 

 

89

 

 

 

306

 

 

 

 

30

 

 

 

308

 

 

 

443

 

 

 

1,114

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total sales revenue

 

$19,372

 

 

$27,837

 

 

$65,499

 

 

$93,524

 

Total derivative pricing adjustments

 

 

(293 )

 

 

(1,325 )

 

 

824

 

 

 

362

 

Gross revenue

 

$19,079

 

 

$26,512

 

 

$66,323

 

 

$93,886

 

Proceeds before intended use

 

 

12,934

 

 

 

990

 

 

 

23,536

 

 

 

1,695

 

Treatment and selling costs

 

 

(1,417 )

 

 

(5,176 )

 

 

(8,789 )

 

 

(19,190 )

 

 

$30,596

 

 

$22,326

 

 

$81,070

 

 

$76,391

 

 

(1)  Certain fiscal 2024 amounts were reclassified from revenue to cost of sales (see Note 19).

 

Derivative pricing adjustments represent subsequent variations in revenue recognized as an embedded derivative from contracts with customers and are accounted for as financial instruments (see Note 22).